Gessel has advised Pure Biologics on its public offering of shares carried out under an accelerated book-building program and the private offering of new company shares. Jonak i Partnerzy advised the managers.
According to Gessel, the public offering included new series G shares and existing sold shares, offered to qualified investors and selected retail investors. The private offering included new series H shares. The total value of both offerings amounted to approximately PLN 30 million.
“The transaction was carried out based on the investment and offering agreement concluded by the company with Ipopema Securities and the placement agreement,” Gessel informed.
Pure Biologics is a Warsaw Stock Exchange-listed biopharmaceutical company that operates in the field of immuno-oncology, autoimmunity, and neurological rare diseases, conducting research using technological platforms for the selection of active particles – antibodies and aptamers.
The Gessel team included Partner Krzysztof Marczuk, Managing Associate Magdalena Szeplik, Senior Associates Michal Wielinski and Jakub Rowicki, and Associates Maciej Kowalski and Piotr Blank.
The Jonak i Partnerzy team included Managing Partner Jacek Jonak, Partner Szymon Banach, and Associate Danuta Pociecha.